ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald May 22, 2026 07:26AM
ORIC Pharmaceuticals (ORIC) Reiterated at Overweight by Cantor Fitzgerald Apr 1, 2026 06:59AM
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC): "today’s move seems like an over-reaction" Mar 9, 2026 02:27PM
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC) Sep 26, 2025 06:42AM
Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharmaceuticals (ORIC) May 29, 2025 06:42AM


May 29, 2025 06:20AM Cantor Fitzgerald on ORIC Pharmaceuticals (ORIC): 'Solid Update in Prostate Cancer for ORIC-944'
May 21, 2025 10:08AM ORIC Pharmaceuticals Inc. (ORIC) Shares Continue Strength Follow Y'Day Sell side Comments, +6pct
May 20, 2025 09:59AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)
Feb 10, 2025 11:12AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC) Following Possible ASCO-GU Feb 13 News Title Leak
Feb 4, 2025 09:38AM Cantor Fitzgerald Reiterates Overweight Rating on ORIC Pharamceuticals (ORIC)
Feb 23, 2024 06:01AM Cantor Fitzgerald Starts ORIC Pharamceuticals (ORIC) at Overweight, 'offers attractive risk/reward'